Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 17252175 | ANTI-CD40 ANTIBODIES FOR USE IN TREATING AUTOIMMUNE DISEASE | December 2020 | April 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17116260 | IDENTIFICATION OF A T CELL EPITOPE OF PREVOTELLA COPRI THAT INDUCES T CELL RESPONSES IN PATIENTS WITH REHUMATOID ARTHRITIS | December 2020 | January 2024 | Allow | 37 | 2 | 1 | Yes | No |
| 17116265 | ANTIBODY BINDING SPECIFICALLY TO MUC1 AND USE THEREOF | December 2020 | June 2023 | Allow | 30 | 1 | 0 | No | No |
| 17099974 | IDENTIFICATION OF PROTEIN ASSOCIATED WITH HEPATOCELLULAR CARCINOMA, GLIOBLASTOMA AND LUNG CANCER | November 2020 | June 2023 | Abandon | 31 | 1 | 0 | No | No |
| 17097044 | PROTEIN PRODUCTION IN FILAMENTOUS FUNGAL CELLS IN THE ABSENCE OF INDUCING SUBSTRATES | November 2020 | February 2025 | Abandon | 51 | 2 | 0 | Yes | No |
| 17055387 | A CD79-SPECIFIC CHIMERIC ANTIGEN RECEPTOR | November 2020 | November 2024 | Allow | 48 | 1 | 1 | Yes | No |
| 17084886 | RECOMBINANT ORGANISMS AND METHODS FOR PRODUCING GLYCOMOLECULES WITH LOW SULFATION | October 2020 | May 2024 | Abandon | 43 | 0 | 1 | No | No |
| 17077456 | ANTIBODIES AND METHODS OF USE THEREOF | October 2020 | July 2024 | Abandon | 45 | 2 | 1 | No | No |
| 17040519 | METHODS OF MAKING AND USING GUIDANCE AND NAVIGATION CONTROL PROTEINS | September 2020 | February 2025 | Abandon | 52 | 3 | 1 | No | No |
| 17040513 | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHOD OF MAKING AND USING THEREOF | September 2020 | March 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 16979209 | COMPOSITIONS AND METHODS FOR DETECTING MYCOBACTERIUM TUBERCULOSIS | September 2020 | October 2024 | Abandon | 49 | 1 | 1 | No | No |
| 16960521 | MULTISPECIFIC ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF | July 2020 | October 2023 | Abandon | 39 | 2 | 1 | No | No |
| 16958844 | ANTIMICROBIAL NANOBODIES | June 2020 | October 2023 | Abandon | 39 | 1 | 1 | No | No |
| 16954484 | WNT SURROGATE MOLECULES AND USES THEREOF | June 2020 | February 2023 | Allow | 32 | 1 | 1 | No | No |
| 16767085 | POLYPEPTIDE INCLUDING ANTIGEN-BINDING DOMAIN AND CARRYING SECTION | May 2020 | February 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 16860552 | Combination therapy with targeted OX40 agonists | April 2020 | January 2024 | Abandon | 44 | 2 | 1 | No | No |
| 16860406 | METHOD FOR IN VIVO GENERATION OF MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES | April 2020 | June 2024 | Allow | 49 | 3 | 1 | Yes | No |
| 16759083 | IGG1 FC MONOMER AND APPLICATION THEREOF | April 2020 | August 2024 | Allow | 51 | 5 | 1 | Yes | No |
| 16652932 | T CELL RECEPTORS FOR IMMUNOTHERAPY | April 2020 | May 2024 | Allow | 49 | 2 | 0 | No | No |
| 16825482 | USES OF AMPHIPHILES IN IMMUNE CELL THERAPY AND COMPOSITIONS THEREFOR | March 2020 | June 2025 | Allow | 60 | 4 | 1 | No | Yes |
| 16648369 | IMMUNOTOXINS WITH ALBUMIN BINDING DOMAIN | March 2020 | June 2023 | Allow | 39 | 3 | 1 | Yes | No |
| 16816814 | Manufacturing Methods for Producing Anti-IL12/IL23 Antibody Compositions | March 2020 | July 2024 | Abandon | 52 | 2 | 1 | No | Yes |
| 16635878 | BISPECIFIC ANTIBODIES AND USES THEREOF | January 2020 | March 2024 | Allow | 49 | 3 | 1 | Yes | No |
| 16635506 | ANTIBODIES WITH FUNCTIONAL DOMAINS IN THE ELBOW REGION BETWEEN VARIABLE AND CONSTANT DOMAIN | January 2020 | February 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16633423 | THREE-DIMENSIONAL STRUCTURE-BASED HUMANIZATION METHOD | January 2020 | January 2023 | Allow | 36 | 1 | 0 | Yes | No |
| 16626721 | CHIMERIC ANTIBODY IMMUNE EFFCTOR CELL ENGAGERS AND METHODS OF USE THEREOF | December 2019 | September 2023 | Allow | 44 | 3 | 1 | Yes | No |
| 16625628 | HETERODIMERIC BISPECIFIC ANTIBODIES | December 2019 | August 2024 | Allow | 56 | 4 | 1 | Yes | No |
| 16717189 | Methods of Producing Heterodimeric Antibodies | December 2019 | May 2025 | Allow | 60 | 5 | 1 | Yes | Yes |
| 16698285 | T CELL ENGAGING AGENTS AND METHODS OF USE THEREOF | November 2019 | June 2024 | Abandon | 55 | 4 | 1 | No | No |
| 16616714 | MULTISPECIFIC MOLECULES THAT BIND TO MYELOPROLIFERATIVE LEUKEMIA (MPL) PROTEIN AND USES THEREOF | November 2019 | June 2025 | Abandon | 60 | 6 | 1 | No | No |
| 16615123 | MULTI-SPECIFIC ANTIBODIES AND METHODS OF MAKING AND USING THEREOF | November 2019 | June 2025 | Allow | 60 | 3 | 1 | Yes | No |
| 16615124 | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHOD OF MAKING AND USING THEREOF | November 2019 | February 2023 | Abandon | 39 | 2 | 1 | Yes | No |
| 16614786 | Antibody Chemically Induced Dimerizer (AbCID) as Molecular Switches for Regulating Cellular Therapies | November 2019 | January 2024 | Allow | 50 | 4 | 1 | Yes | No |
| 16613774 | ACTIVATABLE ANTIBODIES AND METHODS OF USE THEREOF | November 2019 | November 2023 | Allow | 48 | 3 | 1 | Yes | No |
| 16610188 | STABLE FORMULATIONS OF ANTI-TIGIT ANTIBODIES ALONE AND IN COMBINATION WITH PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | November 2019 | May 2024 | Abandon | 54 | 5 | 0 | No | No |
| 16498534 | COMPOSITIONS AND METHODS FOR DETECTING LUNG CANCER | September 2019 | October 2023 | Allow | 49 | 3 | 1 | Yes | No |
| 16493751 | PD-L2 VARIANT IMMUNOMODULATORY PROTEINS AND USES THEREOF | September 2019 | March 2023 | Allow | 42 | 2 | 1 | Yes | No |
| 16520293 | MULTISPECIFIC POLYPEPTIDE CONSTRUCTS CONTAINING A CONSTRAINED CD3 BINDING DOMAIN AND A RECEPTOR BINDING REGION AND METHODS OF USING THE SAME | July 2019 | September 2024 | Allow | 60 | 4 | 1 | Yes | No |
| 16472233 | HETERODIMERIC ANTIGEN BINDING PROTEINS | June 2019 | July 2023 | Abandon | 49 | 3 | 1 | No | No |
| 16466018 | A CD33-, CD16- AND CD123-SPECIFIC SINGLE CHAIN TRIPLEBODY | June 2019 | November 2023 | Allow | 53 | 2 | 1 | Yes | No |
| 16418328 | PSMA BINDING AGENTS AND USES THEREOF | May 2019 | April 2023 | Allow | 47 | 3 | 1 | Yes | No |
| 16462274 | ANTIBODY DRUG CONJUGATES | May 2019 | September 2023 | Abandon | 52 | 2 | 1 | No | No |
| 16349958 | ENGINEERED ANTIBODIES AND USES THEREOF | May 2019 | December 2022 | Allow | 43 | 2 | 0 | Yes | No |
| 16380963 | MULTISPECIFIC POLYPEPTIDE CONSTRUCTS HAVING CONSTRAINED CD3 BINDING AND RELATED METHODS AND USES | April 2019 | June 2023 | Abandon | 50 | 3 | 1 | No | No |
| 16337163 | THERAPEUTIC MULTI-TARGETING CONSTRUCTS AND USES THEREOF | March 2019 | February 2022 | Abandon | 35 | 3 | 1 | Yes | No |
| 16335373 | BISPECIFIC TRIVALENT ANTIBODIES BINDING TO CLAUDIN6 OR CLAUDIN18.2 AND CD3 FOR TREATMENT OF CLAUDIN EXPRESSING CANCER DISEASES | March 2019 | June 2023 | Allow | 51 | 2 | 1 | Yes | No |
| 16332549 | Marker and Target as a Diagnostic Variable and Target for Therapy of Metastatic Cancer | March 2019 | March 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16271410 | BISPECIFIC ANTIGEN-BINDING MOLECULES AND METHODS OF USE | February 2019 | October 2023 | Allow | 56 | 4 | 1 | No | Yes |
| 16303530 | ANTIBODIES AND METHODS OF MAKING SAME | November 2018 | February 2023 | Allow | 50 | 2 | 1 | Yes | No |
| 16094416 | CANCER GENE THERAPY TARGETING CD47 | October 2018 | January 2023 | Allow | 51 | 3 | 1 | Yes | No |
| 16037759 | ANTIBODIES AGAINST CLAUDIN 18.2 USEFUL IN CANCER DIAGNOSIS | July 2018 | December 2023 | Allow | 60 | 6 | 1 | No | No |
| 15616869 | CD33 SPECIFIC CHIMERIC ANTIGEN RECEPTORS | June 2017 | June 2023 | Allow | 60 | 5 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner CHEONG, CHEOM-GIL.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner CHEONG, CHEOM-GIL works in Art Unit 1645 and has examined 52 patent applications in our dataset. With an allowance rate of 61.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 49 months.
Examiner CHEONG, CHEOM-GIL's allowance rate of 61.5% places them in the 23% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by CHEONG, CHEOM-GIL receive 2.71 office actions before reaching final disposition. This places the examiner in the 76% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by CHEONG, CHEOM-GIL is 49 months. This places the examiner in the 8% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +63.6% benefit to allowance rate for applications examined by CHEONG, CHEOM-GIL. This interview benefit is in the 97% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 29.7% of applications are subsequently allowed. This success rate is in the 60% percentile among all examiners. Strategic Insight: RCEs show above-average effectiveness with this examiner. Consider whether your amendments or new arguments are strong enough to warrant an RCE versus filing a continuation.
This examiner enters after-final amendments leading to allowance in 35.0% of cases where such amendments are filed. This entry rate is in the 54% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 122.2% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 2% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.